By Admin at 16 May 2016
Together, U.S. and Russian researchers have identified several driver mutations for lung cancer, which they believe may be responsive to targeted therapies and immunotherapy.
58
Current Gateway-funded clinical trials
150+
Clinical trials funded at leading institutions worldwide
$16.56
Funds one patient for one day at a Gateway-funded clinical trial
